Unmet Demands Create Opportunity for Blockbuster Products for Treating Myelofibrosis


Published Date : Mar 06, 2017

ALBANY, New York, March 06, 2017: MarketResearchReports.biz has added a new market study to its repository, titled “Opportunity Analyzer: Myelofibrosis - Opportunity Analysis And Forecasts To 2025.” Myelofibrosis (MF) is a rare and serious blood disorder, which is characterized by bone marrow fibrosis. It hampers the body’s normal production of blood cells. At present, there is just one approved drug, Incyte/Novartis Jakafi (ruxolitinib), for the treatment of MF, and other conventional therapies leveraged to treat MF are off-label. Some of the off-label therapies are cytoreductive drug, androgen therapies, erythropoiesis-stimulating agents, immunomodulatory imide drugs, and anti-fibrotic agents. 

However, none of the available drugs can cure. The only potentially curative intervention is allogeneic stem cell transplant (allo-SCT) and it is available to a very small percentage of eligible patients because of the high risk of morbidity and mortality. Hence, there is a significant unmet need for the treatment of MF.

The report brings to the fore the substantial dearth of novel drugs to treat myelofibrosis, both to lessen complications pertaining to MF and to reverse the course of the disease. It sheds light on the opportunities for new market players in the market whose value is likely to increase twofold from 2015 to 2025. Some of the factors that will foster the growth in the market for myelofibrosis drugs are the unveiling of pipeline drugs – particularly second-line treatments for patients who are refractory to Jakafi, growing instances of the disorder, and a surge in the use of drugs for splenomegaly, and constitutional symptoms in the European Union and Japan. 

For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/959624 

High cost involved in treatment of myelofibrosis has crimped its market growth so far and the unmet needs are expected to be only partly resolved by the prominent pipeline drugs. Further, at present there are no approved or major pipeline drugs for anemia associated with myelofibrosis.

Any drug that can address this need will most likely be a big hit in the market. 

The report provides a thorough overview of MF that includes epidemiology, etiology, pathophysiology, symptoms, diagnosis, treatment guidelines, and disease management. It uncovers the annual revenue in the MF therapeutics market and presents crucial figures related to average cost of therapy, treatment usage, and future revenue. It presents an assessment of the competitive landscape, characterization of the market, unmet needs, and clinical trial mapping. 

From a geographical standpoint, North America accounts for a maximum share in the global myelofibrosis market in terms of value. This is because of the rising awareness and high occurrence of the malady, greater percentage of income devoted to healthcare, and favorable reimbursement policies. In the years ahead, Asia Pacific is slated to account for a substantial share in the market due to a large elderly population base, rising fortunes of the people and bettering healthcare facilities. 

To order report Call Toll Free: 866-997-4948 or send an email on sales@marketresearchreports.biz